Contact information
Type
Scientific
Primary contact
Prof Andrew Pollard
ORCID ID
Contact details
University of Oxford
Rm 02-46-07
Childrens Hospital
John Radcliffe
Oxford
OX3 9DU
United Kingdom
+44 (0)1865 234226
andrew.pollard@paediatrics.ox.ac.uk
Additional identifiers
EudraCT number
ClinicalTrials.gov number
Protocol/serial number
2009/04
Study information
Scientific title
A randomised open-label immunogenicity study of the 10 Valent Pneumococcal vaccine (PCV10) given as part of the routine infant immunisation schedule to children in Kathmandu, Nepal
Acronym
PCV10
Study hypothesis
A 2+1 schedule of the 10 valent pneumococcal conjugate vaccine will provide a good serological response and that this will be non-inferior to a 3+0 schedule.
Ethics approval
1. Oxford Tropical Research Ethics Committee (OxTREC) approved on the 4th December 2009 (ref: 61/09)
2. Nepal Health Research Council Ethics Committee approved on the 21st January 2010 (ref: 807)
Study design
Single-centre interventional unblinded randomised controlled trial
Primary study design
Interventional
Secondary study design
Randomised controlled trial
Trial setting
Hospitals
Trial type
Prevention
Patient information sheet
Not available in web format, please use the contact details below to request a patient information sheet
Condition
Pneumococcus
Intervention
1. The proportion of participants with vaccine pneumococcal serotype-specific IgG antibody concentrations greater than or equal to 0.2 micrograms/mL at 18 weeks of age, 1 month following primary immunisation with PCV10 at 6, 10 and 14 weeks (3 + 0 group) and the proportion of participants with vaccine pneumococcal serotype-specific IgG antibody concentrations greater than or equal to 0.2 micrograms/mL at 18 weeks of age, 1 month following primary immunisation with PCV10 at 6 and 14 weeks of age (2 + 1 group) and to demonstrate non-inferiority (within 10% levels) of the 2 + 1 group versus 3 + 0 group for this proportion for each of serotypes 1, 5 and 14.
2. The proportion of participants with vaccine pneumococcal serotype-specific IgG antibodies greater than or equal to 0.2 micrograms/mL at 18 weeks and 10 months of agefor each of the three study groups
3. The proportion of participants with vaccine pneumococcal serotype-specific opsonophagocytic activity greater than or equal to 8 at 18 weeks and 10 months of age for each of the three study groups
4. The vaccine pneumococcal serotype-specific geometric mean IgG antibody concentrations at 18 weeks and 10 months of age in infants in each of the three study groups
5. The vaccine pneumococcal serotype-specific geometric mean opsonophagocytic titres at 18 weeks and 10 months of age in infants in each of the three study groups
6. The proportion of participants in the 2+1 group with vaccine pneumococcal serotype-specific IgG antibody concentrations greater than or equal to 0.2 micrograms/mL prior to receiving a booster at 9 months of age
7. The proportion of participants in the 2+1 group with vaccine pneumococcal serotype opsonophagocytic activity titre greater than or equal to 8 prior to receiving a booster dose of PCV10 at 9 months of age
8. The vaccine pneumococcal serotype-specific geometric mean opsonophagocytic titres and geometric mean IgG antibody concentrations in infants in the 2+1 group prior to receiving a booster dose of PCV10 at 9 months of age
9. The nasopharyngeal pneumococcal serotype-specific carriage rates, at 9 months of age, following immunisation with a PCV10 i.e. post-dose 3 in 3+0 schedule, post-dose 2 in 2+1 schedule and those not receiving the pneumococcal vaccine
10. Protein D-specific IgG antibody geometric mean concentrations in infants in the control and 3+0 groups at the age of 18 weeks and 10 months and in the 2+1 group at the age of 18 weeks, 9 months and 10 months
Participants in the 3+0 and 2+1 groups will be followed until 10 months of age and those in the control group will be followed until 11 months of age.
Intervention type
Drug
Phase
Not Applicable
Drug names
10 valent pneumococcal vaccine (PCV10)
Primary outcome measures
The proportion of participants with IgG antibodies against serotypes 1, 5 and 14 greater than or equal to 0.2 micrograms/mL 1 month post-dose 3 at age of 10 months after receiving PCV10 at 6 weeks, 14 weeks and 9 months (2 + 1 group).
Secondary outcome measures
1. The proportion of participants with vaccine pneumococcal serotype-specific IgG antibody concentrations greater than or equal to 0.2 micrograms/mL at 18 weeks of age, 1 month following primary immunisation with PCV10 at 6, 10 and 14 weeks (3 + 0 group) and the proportion of participants with vaccine pneumococcal serotype-specific IgG antibody concentrations greater than or equal to 0.2 micrograms/mL at 18 weeks of age, 1 month following primary immunisation with PCV10 at 6 and 14 weeks of age (2 + 1 group) and to demonstrate non-inferiority (within 10% levels) of the 2 + 1 group versus 3 + 0 group for this proportion for each of serotypes 1, 5 and 14.
2. The proportion of participants with vaccine pneumococcal serotype-specific IgG antibodies greater than or equal to 0.2 micrograms/mL at 18 weeks and 10 months of agefor each of the three study groups
3. The proportion of participants with vaccine pneumococcal serotype-specific opsonophagocytic activity greater than or equal to 8 at 18 weeks and 10 months of age for each of the three study groups
4. The vaccine pneumococcal serotype-specific geometric mean IgG antibody concentrations at 18 weeks and 10 months of age in infants in each of the three study groups
5. The vaccine pneumococcal serotype-specific geometric mean opsonophagocytic titres at 18 weeks and 10 months of age in infants in each of the three study groups
6. The proportion of participants in the 2+1 group with vaccine pneumococcal serotype-specific IgG antibody concentrations greater than or equal to 0.2 micrograms/mL prior to receiving a booster at 9 months of age
7. The proportion of participants in the 2+1 group with vaccine pneumococcal serotype opsonophagocytic activity titre greater than or equal to 8 prior to receiving a booster dose of PCV10 at 9 months of age
8. The vaccine pneumococcal serotype-specific geometric mean opsonophagocytic titres and geometric mean IgG antibody concentrations in infants in the 2+1 group prior to receiving a booster dose of PCV10 at 9 months of age
9. The nasopharyngeal pneumococcal serotype-specific carriage rates, at 9 months of age, following immunisation with a PCV10 i.e. post-dose 3 in 3+0 schedule, post-dose 2 in 2+1 schedule and those not receiving the pneumococcal vaccine
10. Protein D-specific IgG antibody geometric mean concentrations in infants in the control and 3+0 groups at the age of 18 weeks and 10 months and in the 2+1 group at the age of 18 weeks, 9 months and 10 months
Overall trial start date
02/05/2010
Overall trial end date
31/10/2011
Reason abandoned
Eligibility
Participant inclusion criteria
1. Parent/guardian of participant is willing and able to give informed consent for participation in the study
2. In good health as determined by:
2.1. Medical history
2.2. Physical examination
2.3. Clinical judgement of the investigator
3. Male or female, aged 40 - 60 days at time of first study vaccination
4. Participants residing in Kathmandu
5. Parents able (in the Investigators opinion) and willing to comply with all study requirements
Participant type
Healthy volunteer
Age group
Child
Gender
Both
Target number of participants
A total of 390 participants (3+0 group = 120; 2+1 group = 120; control group = 150)
Participant exclusion criteria
1. Parent/guardian unwilling or unable to give written informed consent to participate in the study
2. Previous immunisation (excluding BCG and hepatitis B) or planned vaccination during the study period with vaccine not foreseen by this study protocol except influenza vaccine when locally recommended
3. Premature birth (less than 37 weeks gestation)
4. Previous hospital admission
5. Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the study, or may influence the result of the study, or the participant's ability to participate in the study
6. Use of any investigational or non-registered product (drug or vaccine) within 30 days preceding the vaccination, or planned use during the study period
7. Concurrently participating in another clinical study, at any time during the study period, in which the participant has been or will be exposed to an investigational or a non-investigational product (pharmaceutical product or device)
Recruitment start date
02/05/2010
Recruitment end date
31/10/2011
Locations
Countries of recruitment
Nepal
Trial participating centre
University of Oxford
Oxford
OX3 9DU
United Kingdom
Sponsor information
Organisation
University of Oxford (UK)
Sponsor details
c/o Heather House
Clinical Trials & Research Governance
Manor House
John Radcliffe Hospital
Headington
Oxford
OX3 9DU
United Kingdom
+44 (0)1865 222757
heather.house@admin.ox.ac.uk
Sponsor type
University/education
Website
Funders
Funder type
Industry
Funder name
University of Oxford (UK)
Alternative name(s)
Funding Body Type
Funding Body Subtype
Location
Funder name
GlaxoSmithKline (GSK) (UK)
Alternative name(s)
Funding Body Type
Funding Body Subtype
Location
Results and Publications
Publication and dissemination plan
Not provided at time of registration
Intention to publish date
Participant level data
Not provided at time of registration
Results - basic reporting
Publication summary
2015 results in: http://www.ncbi.nlm.nih.gov/pubmed/25701560